Subscribe

GSK plc (GSK.L)

GBp1,909.50 -44.00 (-2.25%)
GB LSE Healthcare Drug Manufacturers - General
Address 980 Great West Road TW8 9GS
Brentford, GB
CEO Luke Victor Miels
Website gsk.com
IPO 1988-07-01
ISIN GB00BN7SWP63

Explore sections of this company profile

Also trades on Deutsche Börse · GS7.DE (EUR) London Stock Exchange · GSK.L (GBp) New York Stock Exchange · GSK (USD) Other OTC · GLAXF (USD) Swiss Exchange · GSK.SW (CHF)
Description

GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.

News Sentiment (7d)
59 Neutral

Based on only 1 article — low confidence

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp1,909.50 -44.00 (-2.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.29
Float Shares
3.86B
Free Float %
96.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.90% -2.59% -2.44% -14.52% +5.05% +3.12% +24.85% +37.24% +39.24% +28.91% +149.36%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (3 ratings, all time) Buy
Price Targets & DCF
Current price
1,909.50
DCF (Unlevered) 7,061.11 +269.8%
DCF (Levered) 3,705.15 +94.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 26% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 6 +1
Hold 13 0
Sell 2 0
Strong Sell 2 0
Quality scores
Altman Z-Score
2.13
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    +4.1% Q1'26: +1.5% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +123.6% ★ Q1'26: +9.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +24.8% ★ Q1'26: +9.1% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - General: +19.4%
    +24.8% ★ Q1'26: +30.3% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - General: +10.2%
    +22.6% ★ Q1'26: +24.0% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -0.6% ★ Q1'26: -1.5% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    1.49× Q1'26: 1.72× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.30) × ERP
WACC = 81% × Ke + 19% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 7,061.11 Current price: 1,909.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2001
actual 		Dec 2002
actual 		Dec 2003
actual 		Dec 2004
actual 		Dec 2005
actual 		Dec 2006
actual 		Dec 2007
actual 		Dec 2008
actual 		Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
16 Rev. Ana.
12 EPS Ana. 		Dec 2027
19 Rev. Ana.
13 EPS Ana. 		Dec 2028
16 Rev. Ana.
8 EPS Ana. 		Dec 2029
15 Rev. Ana.
6 EPS Ana. 		Dec 2030
15 Rev. Ana.
6 EPS Ana.
Revenue
20.53B
est: 20.81B (-1.3%)
21.21B
est: 21.48B (-1.3%)
21.44B
est: 21.99B (-2.5%)
19.99B
est: 20.78B (-3.8%)
21.66B
est: 21.69B (-0.1%)
23.23B
est: 23.78B (-2.3%)
22.72B
est: 22.97B (-1.1%)
24.35B
est: 24.37B (-0.1%)
28.37B
est: 28.57B (-0.7%)
28.39B
est: 28.85B (-1.6%)
27.39B
est: 28.28B (-3.2%)
26.43B
est: 27.00B (-2.1%)
26.51B
est: 26.87B (-1.4%)
23.01B
est: 23.47B (-2.0%)
23.92B
est: 23.89B (+0.2%)
27.89B
est: 27.73B (+0.6%)
30.19B
est: 30.08B (+0.3%)
30.82B
est: 30.63B (+0.6%)
33.75B
est: 33.64B (+0.3%)
34.10B
est: 34.09B (+0.0%)
24.70B
est: 33.95B (-27.3%)
29.32B
est: 29.14B (+0.6%)
30.33B
est: 31.45B (-3.6%)
31.38B
est: 31.13B (+0.8%)
32.67B
est: 32.50B (+0.5%)
33.79B
33.05B – 34.20B
+4.0% YoY
35.47B
34.25B – 37.73B
+5.0% YoY
36.48B
36.44B – 36.52B
+2.9% YoY
37.95B
36.88B – 39.41B
+4.0% YoY
37.27B
36.22B – 38.70B
-1.8% YoY
EBITDA
6.92B
est: 7.56B (-8.5%)
6.54B
est: 5.48B (+19.2%)
7.24B
est: 6.31B (+14.8%)
6.92B
est: 6.64B (+4.3%)
8.04B
est: 7.21B (+11.5%)
9.05B
est: 8.09B (+11.9%)
8.74B
est: 8.37B (+4.4%)
8.51B
est: 8.74B (-2.7%)
10.18B
est: 8.48B (+20.0%)
5.52B
est: 8.75B (-36.9%)
10.05B
est: 3.90B (+157.5%)
8.76B
est: 7.86B (+11.5%)
8.74B
est: 7.27B (+20.2%)
5.10B
est: 6.33B (-19.4%)
12.81B
est: 3.90B (+228.9%)
4.39B
est: 13.41B (-67.2%)
6.13B
est: 3.19B (+92.0%)
7.33B
est: 3.15B (+132.6%)
9.38B
est: 6.09B (+54.0%)
10.16B
est: 7.61B (+33.5%)
6.45B
est: 7.89B (-18.2%)
8.63B
est: 8.09B (+6.6%)
9.14B
est: 13.25B (-31.0%)
6.68B
est: 13.18B (-49.4%)
11.88B
est: 13.69B (-13.2%)
14.23B
13.92B – 14.41B
+4.0% YoY
14.94B
14.43B – 15.89B
+5.0% YoY
15.37B
15.35B – 15.38B
+2.9% YoY
15.99B
15.53B – 16.60B
+4.0% YoY
15.70B
15.26B – 16.30B
-1.8% YoY
EBIT
6.10B
est: 5.34B (+14.4%)
5.71B
est: 4.89B (+16.9%)
6.38B
est: 5.68B (+12.3%)
6.06B
est: 6.04B (+0.4%)
7.13B
est: 6.34B (+12.6%)
8.09B
est: 7.55B (+7.3%)
7.72B
est: 7.57B (+2.0%)
7.28B
est: 8.06B (-9.7%)
8.62B
est: 8.29B (+4.0%)
3.84B
est: 8.50B (-54.8%)
8.63B
est: 3.71B (+132.7%)
7.32B
est: 7.45B (-1.8%)
7.33B
est: 7.36B (-0.4%)
3.62B
est: 6.38B (-43.3%)
11.18B
est: 3.71B (+201.4%)
2.62B
est: 12.91B (-79.7%)
4.21B
est: 2.83B (+48.9%)
5.48B
est: 4.27B (+28.2%)
7.04B
est: 5.80B (+21.3%)
7.81B
est: 7.34B (+6.5%)
4.33B
est: 7.61B (-43.1%)
6.48B
est: 7.80B (-16.9%)
6.84B
est: 8.68B (-21.2%)
4.12B
est: 8.64B (-52.3%)
8.11B
est: 8.97B (-9.7%)
9.33B
9.13B – 9.44B
+4.0% YoY
9.79B
9.46B – 10.42B
+5.0% YoY
10.07B
10.06B – 10.08B
+2.9% YoY
10.48B
10.18B – 10.88B
+4.0% YoY
10.29B
10.00B – 10.68B
-1.8% YoY
Net Income
3.10B
est: 4.75B (-34.7%)
3.94B
est: 3.19B (+23.2%)
4.49B
est: 4.03B (+11.5%)
3.91B
est: 4.25B (-8.0%)
4.69B
est: 4.48B (+4.7%)
5.39B
est: 5.15B (+4.7%)
5.21B
est: 5.22B (-0.2%)
4.60B
est: 5.53B (-16.8%)
5.53B
est: 5.35B (+3.5%)
1.63B
est: 5.59B (-70.7%)
5.26B
est: 1.60B (+228.5%)
4.50B
est: 5.02B (-10.4%)
5.44B
est: 4.54B (+19.6%)
2.76B
est: 4.75B (-41.9%)
8.42B
est: 2.84B (+196.3%)
912.00M
est: 9.74B (-90.6%)
1.53B
est: 992.33M (+54.4%)
3.62B
est: 1.57B (+131.5%)
4.65B
est: 3.83B (+21.2%)
5.75B
est: 4.90B (+17.4%)
4.39B
est: 5.07B (-13.6%)
14.96B
est: 5.20B (+187.4%)
4.93B
est: 4.03B (+22.2%)
2.58B
est: 6.42B (-59.9%)
5.72B
est: 7.01B (-18.4%)
7.36B
6.93B – 7.79B
+5.1% YoY
8.18B
7.46B – 8.90B
+11.1% YoY
8.77B
7.73B – 9.81B
+7.2% YoY
9.01B
8.68B – 9.46B
+2.7% YoY
9.15B
8.82B – 9.61B
+1.6% YoY
SGA
7.47B
est: 8.05B (-7.3%)
8.04B
est: 8.68B (-7.4%)
7.60B
est: 7.72B (-1.6%)
7.20B
est: 7.15B (+0.8%)
7.25B
est: 7.35B (-1.3%)
7.26B
est: 7.96B (-8.8%)
6.69B
est: 7.03B (-4.8%)
7.17B
est: 7.38B (-2.8%)
8.93B
est: 8.54B (+4.6%)
12.02B
est: 9.29B (+29.4%)
8.22B
est: 12.14B (-32.3%)
8.67B
est: 8.05B (+7.7%)
7.68B
est: 7.82B (-1.8%)
7.33B
est: 7.14B (+2.5%)
7.13B
est: 7.86B (-9.3%)
8.13B
est: 9.40B (-13.6%)
8.25B
est: 9.64B (-14.4%)
9.27B
est: 9.54B (-2.9%)
10.86B
est: 9.95B (+9.1%)
10.46B
est: 11.25B (-7.0%)
6.55B
est: 11.66B (-43.8%)
7.94B
est: 11.95B (-33.5%)
9.01B
est: 9.13B (-1.3%)
10.74B
est: 9.09B (+18.2%)
9.02B
est: 9.44B (-4.4%)
9.81B
9.60B – 9.93B
+4.0% YoY
10.30B
9.95B – 10.96B
+5.0% YoY
10.59B
10.58B – 10.60B
+2.9% YoY
11.02B
10.71B – 11.44B
+4.0% YoY
10.82B
10.52B – 11.24B
-1.8% YoY
EPS
0.63
est: 0.74 (-14.9%)
0.83
est: 0.79 (+4.7%)
0.97
est: 0.87 (+10.9%)
0.85
est: 0.78 (+9.5%)
1.03
est: 0.83 (+23.8%)
1.19
est: 0.99 (+20.7%)
1.18
est: 1.01 (+17.4%)
1.11
est: 1.07 (+3.8%)
1.36
est: 1.22 (+11.8%)
0.40
est: 0.88 (-54.3%)
1.31
est: 1.18 (+10.7%)
1.15
est: 1.15 (-0.2%)
1.41
est: 1.16 (+21.6%)
0.72
est: 0.97 (-25.9%)
2.18
est: 0.77 (+184.2%)
0.24
est: 1.02 (-76.9%)
0.39
est: 1.11 (-64.8%)
0.92
est: 1.16 (-20.2%)
1.17
est: 1.24 (-5.2%)
1.44
est: 1.17 (+23.8%)
1.37
est: 1.11 (+23.5%)
3.71
est: 1.34 (+176.8%)
1.22
est: 0.99 (+22.6%)
0.63
est: 1.55 (-59.2%)
1.41
est: 1.69 (-16.6%)
1.79
1.68 – 1.89
+5.7% YoY
1.96
1.81 – 2.16
+9.9% YoY
2.05
1.88 – 2.38
+4.5% YoY
2.19
2.11 – 2.30
+6.6% YoY
2.22
2.14 – 2.33
+1.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-28 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-27 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-26 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-22 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-21 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-20 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-19 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-18 A- 4/5 5/5 5/5 5/5 1/5 2/5 2/5
2026-05-15 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-14 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-13 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-12 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-11 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-08 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-07 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-06 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-05 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-05-01 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-30 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-29 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-28 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-27 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-24 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-23 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-22 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-21 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-20 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-16 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-15 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
5.44B
OE per share TTM
1.33
Owner's Yield
7.19%
Maintenance CapEx ratio
23.32%
Maint CapEx / Avg PPE
33.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
118.1K
Shares Outstanding
3.99B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Emma Natasha Walmsley Executive Officer 6M female
Luke V. Miels Chief Executive Officer & Director 4M male
Julie Brown Chief Financial Officer & Executive Director 4M female
Jesse L. Goodman Scientific & Medical Expert 61.9K —
Philip C. Thomson President of Global Affairs — male
Roanne Parry Chief People Officer — female
Shobie Ramakrishnan Chief Digital & Technology Officer — female
Constantin Fest Senior Vice President & Head of Investor Relations — male
Tony Wood Chief Scientific Officer and Head of R&D — male
David Simon Redfern President of Corporate Development — male
Diana Conrad Chief People Officer — female
James Ford Senior Vice President & Group General Counsel of Legal & Compliance — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General